Bio-Path Receives Third U.S. Patent Grant Related to Manufacture of Platform Technology
February 10 2021 - 7:00AM
Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company
leveraging its proprietary DNAbilize® liposomal delivery and
antisense technology to develop a portfolio of targeted nucleic
acid cancer drugs, today announced that the United States Patent
and Trademark Office has granted U.S. Patent No. 10,898,506 titled,
"P-ethoxy nucleic acids for liposomal formulation." The new patent
builds on earlier patents granted that protect the platform
technology for DNAbilize®, the Company’s novel RNAi nanoparticle
drugs.
In addition, the United States Patent and Trademark Office has
mailed an Issue Notification for a patent related to the Company’s
lead product candidate, prexigebersen, in combination with either a
cytidine analogue, such as decitabine, or the Bcr-Abl tyrosine
kinase inhibitors dasatinib and nilotinib. Prexigebersen is a
liposomal formulation containing the antisense oligodeoxynucleotide
targeting growth factor receptor-bound protein 2 (Grb2). The new
patent is scheduled to issue as U.S. Patent No. 10,927,379 on
February 23, 2021.
“Our innovative DNAbilize platform improves upon
the drawbacks of traditional approaches, which are limited by the
toxicity induced by either the DNA backbone or the lipid delivery,”
said Peter Nielsen, President and Chief Executive Officer of
Bio-Path Holdings. “DNAbilize overcomes these challenges by
combining a neutral charge P-ethoxy DNA backbone with a neutral
charge liposome. The result is a high payload liposome with DNA
safely delivered inside non-toxic cell membrane-like molecules,
allowing us to deliver antisense DNA in high doses to target cells
through the blood and lymphatic system with no evidence of toxicity
in patients in clinical trials to date, in contrast to other lipid
delivery technologies with dose limiting toxicities.”
“The ’506 patent is the third patent in our family of platform
intellectual property and offers expanded defense of our DNAbilize
platform technology. The ’379 patent will offer target-specific
protection for on-going clinical trials using prexigebersen in
combination with decitabine as a treatment for acute myeloid
leukemia (AML). We continue our efforts to build a fortress of
protection around our technology as it safeguards our platform
technology and target-specific technology, is a deterrent to
would-be competitors and creates value around our core
competencies,” continued Mr. Nielsen.
About Bio-Path Holdings, Inc.
Bio-Path is a biotechnology company developing DNAbilize®, a
novel technology that has yielded a pipeline of RNAi
nanoparticle drugs that can be administered with a
simple intravenous infusion. Bio-Path’s lead product
candidate, prexigebersen (BP1001, targeting the Grb2 protein),
is in a Phase 2 study for blood cancers and prexigebersen-A,
a drug product modification of prexigebersen, is under
consideration by the FDA to commence Phase 1 studies in solid
tumors. This is followed by BP1002, targeting the
Bcl-2 protein, where it is being evaluated in lymphoma
clinical studies.
For more information, please visit the Company's website at
www.biopathholdings.com.
Forward-Looking Statements
This press release contains forward-looking statements that are
made pursuant to the safe harbor provisions of the federal
securities laws. These statements are based on management's current
expectations and accordingly are subject to uncertainty and changes
in circumstances. Any express or implied statements contained in
this press release that are not statements of historical fact may
be deemed to be forward-looking statements. Any statements that are
not historical facts contained in this release are forward-looking
statements that involve risks and uncertainties, including the
impact, risks and uncertainties related to COVID-19 and actions
taken by governmental authorities or others in connection
therewith, Bio-Path’s ability to raise needed additional capital on
a timely basis in order for it to continue its operations,
Bio-Path's ability to have success in the clinical development of
its technologies, the timing of enrollment and release of data in
such clinical studies and the accuracy of such data, limited
patient populations of early stage clinical studies and the
possibility that results from later stage clinical trials with much
larger patient populations may not be consistent with earlier stage
clinical trials, the maintenance of intellectual property rights,
that patents relating to existing or future patent applications
will be issued or that any issued patents will provide meaningful
protection of our drug candidates, risks relating to maintaining
Bio-Path's listing on the Nasdaq Capital Market and such other
risks which are identified in Bio-Path's most recent Annual Report
on Form 10-K, in any subsequent quarterly reports on Form 10-Q and
in other reports that Bio-Path files with the Securities and
Exchange Commission from time to time. These documents are
available on request from Bio-Path Holdings or at www.sec.gov.
Bio-Path disclaims any intention or obligation to update or revise
any forward-looking statements, whether as a result of new
information, future events or otherwise.
Contact Information:
Investors
Will O’ConnorStern Investor Relations,
Inc.212-362-1200will@sternir.com
Doug Morris Investor Relations Bio-Path
Holdings, Inc. 832-742-1369
Bio Path (NASDAQ:BPTH)
Historical Stock Chart
From Aug 2024 to Sep 2024
Bio Path (NASDAQ:BPTH)
Historical Stock Chart
From Sep 2023 to Sep 2024